Global Veterinary Anti-infectives Market
Anti-infectives are the substances which have the ability to counter the malfunction caused by foreign bacteria, fungi, virus, parasites, and among others. Anti-infectives are used to prevent or completely cure of various infectious diseases. These substances prevent the chances of contracting the infection by making the body immune from the specific bacterial infection. Commonly occurred veterinary infectious diseases include zoonotic diseases and foodborne disorders.
Global Veterinary Anti-invectives market Insights
Increase in the global animal adoption rate, a rise in the prevalence of foodborne and zoonotic diseases, increase in the R&D activities for innovation of new products, and government initiations for the animal healthcare are anticipated to fuel the veterinary anti-infectives market. Moreover, increase in the preference for healthy meat and other dairy products, a rise in awareness about the animal infectious diseases, lack of awareness about veterinary vaccines, and growing animal healthcare expenditure expected to boost the veterinary anti-infectives market over the forecast period. However, stringent regulatory policies for veterinary medicines and lack of awareness about the anti-infective drugs in underdeveloped regions might hinder the growth of veterinary anti-infectives market.
The veterinary anti-invectives market is growing at a significant CAGR owing to increase in the animal adoption rate. Market players are actively focusing on the development of novel medicines and vaccines for the prevention or cure of various infectious diseases in animals. The rise in the prevalence of foodborne and zoonotic diseases also expected to propel the veterinary anti-infectives market over the forecast period. Acquisitions and mergers, collaborations, product innovations, and launchings are the strategies followed by the companies for garnering market revenue share in the global veterinary anti-infectives market. For instance, in January 2013, Bayer healthcare acquired Teva’s animal healthcare business including the veterinary anti-infectives for diversifying its veterinary anti-infectives product portfolio. Moreover, In May 2013, Novabay Pharmaceuticals inked a collaboration agreement with Virbac for exploring uses of veterinary anti-infective drug auriclosene.
Veterinary anti-infectives market is segmented on the basis of drug type, disease type, species type, route of administration and end user
Based on the drug type, the market is segmented into the following:
- Anti-viral drugs
- Anti-bacterial drugs
- Anti-fungal drugs
Based on the disease type, the market is segmented into the following:
- Dermatological infections
- Respiratory infections
- Gastrointestinal infections
- Ophthalmic infections
Based on the species type, the market is segmented into the following:
- Farm animals
- Companion animals
Based on the route of administration, the market is segmented into the following:
Based on the distribution channel, the market is segmented into the following:
- Veterinary hospitals
- Veterinary pharmacies
- Online pharmacies
Geographically, veterinary anti-infectives market is segmented into Europe, Asia Pacific, Latin America, North America, and the Middle East and Africa. Increase in the pet animal adoption rate, a rise in animal welfare, growing R&D activities for innovation of novel products, and rise in per capita income are the factors anticipated to fuel the veterinary anti-infectives market in North America region. Europe holds a significant share in the veterinary anti-infectives market owing to rise in prevalence of zoonotic and foodborne diseases, innovation of newer products, a rise in awareness the animal welfare, and animal healthcare expenditure are anticipated to fuel the market in the region. However, the Asia Pacific region has a significant growth over the forecast period due to rise in the rearing of farm animals majorly in India and China, increase in the preference for healthy meat and other dairy products, and rise in the prevalence of infectious diseases are anticipated to fuel the veterinary anti-infectives market.
Some of the players in veterinary anti-infectives market are Zoetis, Inc. (Pfizer) (U.S), Virbac AH Inc. (France), Sanofi S.A. (France), Boehringer Ingelheim Vetmedica, Inc. (Boehringer Ingelheim) (Germany), Bayer HealthCare LLC, (Bayer AG) (Germany), Merck Animal Health (Merck &co. Inc.) (U.S.), Dechra Pharmaceuticals (U.K.), and NovaBay Pharmaceuticals, Inc. (U.S.) to name a few.
Key Market Developments
In March 2016, Dechra Pharmaceuticals acquired Putney Inc. for the expanding the veterinary products portfolio and development of pipeline products including veterinary anti-infectives
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario